The Controlled Trial of Apremilast for Rheumatoid Arthritis Treatment (CARAT)

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL

apremilast

30 mg BID apremilast taken orally for the first 12 weeks followed by responders randomized to either 30 mg BID apremilast (oral) or 30 mg BID placebo (oral) for 8 weeks

OTHER

Placebo

Trial Locations (1)

75231

Baylor Research Institute - Arthritis Care and Research Center, Dallas

Sponsors
All Listed Sponsors
lead

Baylor Research Institute

OTHER